RECURRENT ENDOMETRIAL CANCER
Clinical trials for RECURRENT ENDOMETRIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL CANCER trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug trial halted early: what happened with ART0380?
Disease control TerminatedThis study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The goal was to see if the drug could shrink tumors. The trial was terminated early, so results are limited. Participants had to have stopped…
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Cancer drug combo tested in black women – study ends early
Disease control TerminatedThis study aimed to see if a combination of two drugs, lenvatinib and pembrolizumab, could shrink tumors in Black women whose endometrial cancer had come back. Only 4 people took part before the study was stopped early. The treatment requires ongoing medication and is not a cure.
Matched conditions: RECURRENT ENDOMETRIAL CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC